Turn Therapeutics Inc (TTRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$13.75+8.61%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Operating income loss stays near or below -$1.25 million: metric not reported.
Turn Therapeutics shows progress with a new drug study. They manage losses near $1.2 million operating loss in 2026-Q1. The company has a strong partnership with Medline. New board members improve leadership.
The company keeps losing money with no clear profit path. Earnings estimates remain negative through 2027. Debt and financial obligations may limit growth. Clinical success is not yet proven in sales.
No clear market consensus or price targets exist. The stock price reflects high uncertainty and loss-making status. Our view is cautious given ongoing losses and no revenue.
Breaks if: No new independent directors added within next 4 quarters
Breaks if: Default or failure to manage financial obligations within next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment focused on the healthcare sector. The current thesis state reflects a fragile recovery in recent financial performance, but significant risks remain due to high volatility in the sector and overall economic conditions.
The market appears to have priced in a level of uncertainty given TTRX's recent earnings miss and ongoing capital allocation concerns. However, the recent rise in sector context suggests that some positive momentum is expected, particularly if sector leaders perform well.
Management is on track with key priorities, including advancing clinical trials and managing expenses. However, the high-risk environment and recent negative events could hinder more robust financial performance in the near term.
The thesis hinges on the performance of sector bellwethers and the broader economic outlook. If these companies continue to exceed expectations, TTRX may benefit from the sector's momentum. Conversely, any signs of weakness could negatively impact TTRX's prospects.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has raised concerns about performance. This miss adds pressure to the company's financial standing. The overall market backdrop has also shifted to a risk-off sentiment.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Operating income loss worsens beyond -$1,250,000 next quarter
Control operating losses and negative cash flow to extend runway and support ongoing clinical development.
Breaks if: No positive clinical results published within next 4 quarters
In the next 1 to 3 years, TTRX's performance will depend on both management execution and external market conditions. Not investment advice.